You are here
VAXFORM LLC
UEI: L2PLXD4EA569
# of Employees: 4
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
IND ENABLING STUDIES FOR A GROUP A STREP VACCINE
Amount: $300,000.00To develop vaccines against Group A Streptococcus.
SBIRPhase I2021Department of Health and Human Services National Institutes of Health -
SBIR Phase I: Development of an oral recombinant subunit vaccine to protect against COVID-19
Amount: $256,000.00The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a new self-administered vaccine for COVID-19 using a novel oral delivery platfor ...
SBIRPhase I2020National Science Foundation -
SBIR Phase I: Incorporation of a new adjuvant system to produce a thermally stable, orally administered Diphteria-Tetanus-Pertussis vaccine
Amount: $225,000.00This SBIR Phase I project will test the feasibility of incorporating a novel vaccine technology to diphtheria, tetanus, and acellular pertussis (DTaP) vaccine to produce a thermostable and orally admi ...
SBIRPhase I2019National Science Foundation -
Development of a Recombinant Vaccine Against Streptococcus Pyogenes Infection and Disease
Amount: $749,505.00A vaccine to protect against diseases resulting from infection with Streptococcus pyogenes is under development. This vaccine utilizes a recombinant fusion protein (SpeAB) comprising of genetically d ...
STTRPhase II2013Department of Defense Army -
Development of a Recombinant Vaccine Against Streptococcus Pyogenes Infection and Disease
Amount: $100,000.00In this phase I proposal we propose development studies for a vaccine targeting diseases caused by infection with Streptococcus pyogenes. This vaccine utilizes a recombinant fusion protein comprising ...
STTRPhase I2012Department of Defense Army
